VERTEX PHARMACEUTICALS INC / MA (VRTX) Free cash flow 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$3.2BFY2025 · since FY2016: $179.5M → $3.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.2B | +504.1% |
| FY2024 | -$790.3M | -123.7% |
| FY2023 | $3.3B | -15.0% |
| FY2022 | $3.9B | +63.0% |
| FY2021 | $2.4B | -19.5% |
| FY2020 | $3.0B | +100.4% |
| FY2019 | $1.5B | +27.2% |
| FY2018 | $1.2B | +57.6% |
| FY2017 | $745.5M | +315.2% |
| FY2016 | $179.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating marginVRTX Operating cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →